Sonnet BioTherapeutics Trading Up 2.7 %
Shares of SONN opened at $1.51 on Friday. Sonnet BioTherapeutics has a 52-week low of $1.08 and a 52-week high of $26.40. The business’s fifty day moving average is $1.50 and its 200-day moving average is $3.63.
Wall Street Analysts Forecast Growth
Separately, LADENBURG THALM/SH SH assumed coverage on Sonnet BioTherapeutics in a research note on Monday, November 27th. They issued a “buy” rating on the stock.
Institutional Investors Weigh In On Sonnet BioTherapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC bought a new stake in Sonnet BioTherapeutics during the 2nd quarter worth $33,000. State Street Corp grew its position in Sonnet BioTherapeutics by 96.8% during the 2nd quarter. State Street Corp now owns 130,288 shares of the company’s stock worth $36,000 after acquiring an additional 64,100 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Sonnet BioTherapeutics during the 1st quarter worth $49,000. Geode Capital Management LLC grew its position in Sonnet BioTherapeutics by 485.8% during the 2nd quarter. Geode Capital Management LLC now owns 169,392 shares of the company’s stock worth $83,000 after acquiring an additional 140,476 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Sonnet BioTherapeutics by 1,714.2% during the 2nd quarter. Renaissance Technologies LLC now owns 293,893 shares of the company’s stock worth $144,000 after acquiring an additional 277,693 shares during the last quarter. Institutional investors own 36.77% of the company’s stock.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
- Five stocks we like better than Sonnet BioTherapeutics
- The How and Why of Investing in Biotech Stocks
- MarketBeat Week in Review – 2/5 – 2/9
- Dividend Capture Strategy: What You Need to Know
- Cloudflare results spark analysts reset: 25% upside ahead
- Manufacturing Stocks Investing
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.